Pear Therapeutics, Inc. (PEARQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0197 - Volume
298 - Avg. Volume
15,808 - Market Cap (intraday)
142 - Beta (5Y Monthly) 8.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date May 1, 2024 - May 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology. Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
peartherapeutics.com200
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PEARQ
Performance Overview: PEARQ
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEARQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEARQ
Valuation Measures
Market Cap
14.27k
Enterprise Value
-21.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
0.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.93%
Return on Equity (ttm)
-124.76%
Revenue (ttm)
12.69M
Net Income Avi to Common (ttm)
-75.49M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
59.27M
Total Debt/Equity (mrq)
122.96%
Levered Free Cash Flow (ttm)
-64.18M
Research Analysis: PEARQ
Company Insights: PEARQ
PEARQ does not have Company Insights